SLC5A2 and kidney disorder: This meta-analysis confirms that SGLT2 inhibitors alleviate symptom burden in individuals with HFrEF, HFpEF, and HFmrEF while lowering cardiovascular mortality, heart failure hospitalization, and renal disease progression.